 RALEIGH, NC ACCESSWIRE May 11, 2020 9 Meters Biopharma, Inc NMTR, today announced that it has received a thorough QT TQT study waiver as requested by the Company from the US Food and Drug Administrations Center for Drug Evaluation and Research, pursuant to the Companys development of its co-lead Phase 3 larazotide acetate program in celiac disease. The waiver supports the candidates strong precedent of safety and will potentially streamline the programs timeline and cost-effectiveness. 